She helps patients protect muscle, stabilize nutrition, and maintain healthy habits long after active treatment is complete
Promising safety profile: Early trials report tolerability comparable to incretin-based agents, though higher doses are associated with GI side effects (nausea, diarrhea, vomiting, constipation) Clinical Advantage over Others (Clinical Trial Evidence) Phase 2 obesity studies: At 48 weeks, retatrutide delivered weight reductions up to 24%, far exceeding results reported for monotherapy GLP-1 agents
The pattern we've observed is consistent: patients who address cellular energy metabolism alongside GLP-1 therapy report better sustained energy during caloric restriction and fewer mid-treatment stalls
A: You can, but side effects will be worse
Cormio L, Zizzi V, Bettocchi C et al: Tunica albuginea plication for the correction of penile curvature